That build-up can take time, and could vary depending on the patient and the strain of HIV. The results of the latest Phase Two clinical trial, completed last year with 13 patients, were mixed; some patients saw no drop in their viral load, while others saw a dramatic drop. The scientists are currently working to publish the study results. What's clear is that KP-1461 does eventually destroy HIV in some patients, unlike the current batch of antiretroviral drugs, which limit the reproduction of the virus but fail to destroy it. KP-1461 doesn't have any known side effects, but the worry from the Food and Drug Administration is that a drug that induces mutation in a virus could also cause dangerous mutations in the patient's own DNA. So far it doesn't appear to cause short-term mutations in animal models, but longer-term studies are necessary to eliminate the possibility, said Robert Smith, a professor at the University of Washington who studies other lethal mutagenic drugs. Mutagenic drugs could be used to fight other diseases as well, such as polio, hepatitis C and influenza. KP-1461 is at the forefront of this new avenue of research. "Intellectually this is exciting; it's a very creative approach," said Smith. "From a practical perspective, there are still a lot of questions." Related Links: |
advertisement
Put Discovery News on Your Site!
|
-
our sites
-
video
mobile
-
shop
-
stay connected
-
corporate